Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2010-05-14
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT00410657
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
- Conditions
- Interventions
- Drug: CytarabineDrug: CyclophosphamideDrug: AsparaginaseOther: Laboratory Biomarker AnalysisDrug: Daunorubicin HydrochlorideDrug: MethotrexateDrug: MercaptopurineDrug: Leucovorin CalciumDrug: DexamethasoneDrug: PegaspargaseDrug: Doxorubicin HydrochlorideDrug: PrednisoneDrug: NelarabineDrug: Vincristine SulfateRadiation: Radiation TherapyDrug: Thioguanine
- First Posted Date
- 2006-12-05
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1895
- Registration Number
- NCT00408005
- Locations
- 🇺🇸
Scott and White Memorial Hospital, Temple, Texas, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2016-05-10
- Lead Sponsor
- Silvio Aime
- Target Recruit Count
- 24
- Registration Number
- NCT00406978
- Locations
- 🇮🇹
Div. Univ. Di Ematologia, Az. Osp. San Giovanni Battista, Torino, TO, Italy
🇮🇹Dip. Scienze Mediche & IRCAD-Università, UDA Ematologia, Novara, Italy
🇮🇹Servizio di Ematologia, Azienda Ospedaliera S. Maria Nuova, Reggio Emilia, Italy
A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.
- Conditions
- Interventions
- First Posted Date
- 2006-11-30
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 459
- Registration Number
- NCT00405756
- Locations
- 🇦🇹
University Hospital Innsbruck, Innsbruck, Austria
🇧🇾Republican Scientific and Practical Centre of Radiation Medicine and Human Ecology, Gomel, Belarus
🇧🇪AZ St-Jan Brugge Oostende AV, Brugge, Belgium
Phase I Trial of Docetaxel With Perifosine
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- AEterna Zentaris
- Target Recruit Count
- 39
- Registration Number
- NCT00399087
- Locations
- 🇺🇸
Investigative Site, Johnson City, Tennessee, United States
Combination Chemotherapy in Treating Young Male Patients With Hodgkin's Lymphoma
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Christine Mauz-Körholz
- Target Recruit Count
- 16
- Registration Number
- NCT00398554
- Locations
- 🇨🇭
University Children's Hospital, Zurich, Switzerland
🇩🇪Medizinische Hochschule Hannover, Hannover, Germany
🇩🇪Klinikum Augsburg, Augsburg, Germany
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
- Conditions
- Interventions
- First Posted Date
- 2006-10-20
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 107
- Registration Number
- NCT00390793
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- AIDS Malignancy Consortium
- Target Recruit Count
- 43
- Registration Number
- NCT00389818
- Locations
- 🇺🇸
UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States
🇺🇸Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Virginia Mason Medical Center, Seattle, Washington, United States
Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.
- Conditions
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 60
- Registration Number
- NCT00388635
- Locations
- 🇪🇸
Clínica Universitaria de Navarra, Pamplona, Navarra, Spain
🇪🇸Hospital Clínico San Carlos de Madrid, Madrid, Spain
🇪🇸Hospital Doce de Octubre, Madrid, Spain
Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease
- First Posted Date
- 2006-10-16
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 36
- Registration Number
- NCT00388362
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.